Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
Massachusetts General Hospital
Massachusetts General Hospital
Dana-Farber Cancer Institute
Milton S. Hershey Medical Center
Children's Hospital Medical Center, Cincinnati
Rabin Medical Center
Radiation Therapy Oncology Group
University of Iowa
SCRI Development Innovations, LLC
Wake Forest University Health Sciences
Wake Forest University Health Sciences
University of South Florida
National Institutes of Health Clinical Center (CC)
Northwestern University
Mahidol University
Mercy Research
Medical College of Wisconsin
Northwestern University
Dana-Farber Cancer Institute
Burzynski Research Institute
National Cancer Institute (NCI)
NYU Langone Health
Massachusetts General Hospital
National Cancer Institute (NCI)
University of Utah
SWOG Cancer Research Network
Memorial Sloan Kettering Cancer Center
University of Utah
National Cancer Institute (NCI)
INSYS Therapeutics Inc
Duke University